NASDAQ
12.12.25 | 21:59
81,35 US-Dollar
-0,43 % -0,35
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.11. | Mizuho initiates coverage on Tarsus Pharmaceuticals stock with Outperform rating | 1 | Investing.com | ||
| 20.11. | Mizuho startet Coverage für Tarsus Pharmaceuticals mit "Outperform" und 30 % Kurspotenzial | 2 | Investing.com Deutsch | ||
| 18.11. | Aktie von Tarsus Pharmaceuticals klettert auf Rekordhoch von 76,85 USD | 2 | Investing.com Deutsch | ||
| 05.11. | Tarsus outlines $140M-$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress | 2 | Seeking Alpha | ||
| 05.11. | Tarsus Q3 2025 presentation slides: XDEMVY sales surge 147% YoY to $118.7M | 2 | Investing.com | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 04.11. | Tarsus Q3 2025: XDEMVY-Umsatz schnellt um 147 % auf 118,7 Mio. US-Dollar in die Höhe | 1 | Investing.com Deutsch | ||
| 04.11. | Tarsus Pharmaceuticals: Umsatz und Ergebnis übertreffen Prognosen für Q3 2025 | 2 | Investing.com Deutsch | ||
| 04.11. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | 151 | GlobeNewswire (Europe) | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| 04.11. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.10. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 | 1 | GlobeNewswire (USA) | ||
| 20.10. | Tarsus Pharmaceuticals stock price target raised to $88 from $72 at H.C. Wainwright | 10 | Investing.com | ||
| 07.08. | Tarsus targets 95,000-100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum | 3 | Seeking Alpha | ||
| 06.08. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | 522 | GlobeNewswire (Europe) | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| 06.08. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.08. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 18.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.05. | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | 849 | GlobeNewswire (Europe) | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| 13.01. | Tarsus Pharmaceuticals, Inc: Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care | 819 | GlobeNewswire (Europe) | Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,226 | -0,27 % | Aktien KW 49 Doch noch? Jahresendrallye auf den letzten Drücker? News. Aurubis.Bilfinger. Hochtief. Strabag. Jost. Evotec. Mutares. Tonies. NAGA. 2G Energy. Hausvorteil. Procredit. artec Technologies | Aktien: Diese Woche setzte sich letztendlich nach Rückschlägen die Erholung fort. Am Freitag schaffte der DAX sogar die 24.000er Marke wieder. Eigentlich zu spät für eine Jahresendrallye. Vor allem:... ► Artikel lesen | |
| MODERNA | 25,150 | +0,16 % | Nanexa AB: Nanexa and Moderna enter into license and option agreement for the development of PharmaShell-based products | The agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,110 | +1,73 % | Viking Therapeutics-Aktie: Was kommt 2026? | Kurz vor Jahresende nehmen wir die Aktie von Viking Therapeutics noch einmal unter die Lupe, denn das Unternehmen steht vor einem entscheidenden Jahr für seine Adipositas-Pipeline. Zwar sind keine Zulassungsentscheidungen... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| KUROS BIOSCIENCES | 30,800 | +0,20 % | Kuros Biosciences AG: Kuros Biosciences announces enrollment of first patient in ASTRA study - A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion | Kuros Biosciences announces enrollment of first patient in ASTRA study - A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion
Schlieren (Zürich), Switzerland,... ► Artikel lesen | |
| ABIVAX | 107,40 | +0,19 % | Abivax vor möglicher Übernahme: NBC-Volltreffer liefert +200% Kursgewinn | Nachdem sich die Aktie der französischen Biotechschmiede Abivax in den letzten Monaten schon vervielfachen konnte, verzeichnet sie am heutigen Mittwoch noch einmal einen kräftigen Kurssprung von zeitweise... ► Artikel lesen | |
| RELIEF THERAPEUTICS | 3,155 | +6,23 % | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics and NeuroX Unveil Joint Presentation and Financial Outlook Ahead of Anticipated Business Combination... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,925 | +2,49 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| DENALI THERAPEUTICS | 15,225 | -0,62 % | Denali Therapeutics dips after pricing $200M equity offering | ||
| CYTOMX THERAPEUTICS | 3,544 | -0,84 % | CytomX Therapeutics Inc.: CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer | SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,953 | +2,11 % | Rocket Pharma cut at J.P. Morgan on risks to Danon disease program | ||
| SYNDAX PHARMACEUTICALS | 17,200 | -1,15 % | Syndax Pharmaceuticals, Inc.: Revuforj (revumenib) Named Best New Drug at the Scrip Awards 2025 | ||
| ASCENDIS PHARMA | 185,00 | -1,60 % | $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today | ||
| JASPER THERAPEUTICS | 1,770 | -3,80 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation | Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 2,220 | -6,33 % | Chemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology | - New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a Phase 3 Registration Trial- TEL AVIV... ► Artikel lesen |
TARSUS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 81,35 Euro und damit -0,43 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.